Sumitomo’s FY2024 1H Results Meet Initial Plan amid Restructuring

To read the full story

• Sign In
• Subscribe

Related Article

• Sumitomo Ups FY2025 Forecast on North America-Driven Profit Growth
  November 4, 2025

• Sumitomo Pharma Rejoins PhRMA amid US Tariff Concerns, Posts H1 Forecasts
  August 1, 2025

• Sumitomo Pharma Logs 1st Operating Profit in 3 Years in FY2024
  May 14, 2025

• Sumitomo Ups FY2024 Earnings Outlook, Now Expects Black Ink
  February 3, 2025

• Sumitomo Sales Surge 18% in April-September on 3 Key Brands
  October 31, 2024

• Sumitomo Resolved to Revive Business, Optimize Japan Organization: New CEO
  June 27, 2024

• As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
  May 15, 2024

• Sumitomo Pharma Replaces CEO amid Dismal Earnings
  May 14, 2024

• Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
  May 2, 2024

• Sumitomo’s FY2023 Operating Loss Outlook Swells to 354.9 Billion Yen
  May 2, 2024

• Sumitomo Offloads Entire Stake in Roivant as Earnings Tank
  April 3, 2024

• Sumitomo to Cut Med- to Long-Term Guidance amid Tepid Uptake of New Drivers
  February 1, 2024

• Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
  November 1, 2023

• Sumitomo’s Group Sales Halve in Q1 as Latuda LOE in US Takes Toll
  August 1, 2023

• Sumitomo Incurs 77 Billion Yen Operating Loss in FY2022 on Kynmobi Impairment Charge
  May 16, 2023

• Sumitomo Gears Up for Post-Latuda Growth, Sets 2027 Target Sales to 600 Billion Yen
  May 8, 2023

• Sumitomo Sees Sales Force as Asset to Lure Collabs; Rep Cut Not in the Cards though Trulicity Deal Ended
  February 9, 2023

• Sumitomo Suffers 18.5 Billion Yen Net Loss in April-December on Kynmobi Woes
  February 1, 2023

• Sumitomo Braced for Red Ink to Continue in FY2023 on Latuda LOE
  November 1, 2022

• Sumitomo Posts 7.3 Billion Yen Net Loss in H1 on Kynmobi Write-Down
  November 1, 2022

• Sumitomo to Incur 54 Billion Yen in Impairment Loss on Kynmobi
  October 7, 2022

• Sumitomo’s Q1 Sales Zoom 22% on FX, Cancer Drug License Fee
  August 1, 2022

• Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches
  May 16, 2022

• Sumitomo’s FY2021 Sales Up 8.5% on Otsuka Pact, North America/China Growth; Chairman Tada to Retire
  May 16, 2022

• Sumitomo Dainippon’s 9-Month Profit Sinks 33.5% on US Promotions, Other Factors
  February 1, 2022

• Otsuka Collaboration “More Positive” than Solo Even If Profits Shared: Sumitomo Dainippon Chief
  October 28, 2021

• Sumitomo Dainippon’s H1 Sales Surge 12.3% on Otsuka Deal
  October 28, 2021

• Sumitomo Dainippon’s Q1 Sales Skid 2.0% on Lower Latuda Revenue
  July 30, 2021

• Sumitomo Dainippon Sees 6.9% Sales Growth on Latuda, Diabetes Med; Name Change Announced
  May 13, 2021

• Sumitomo Dainippon Logs Double-Digit Growth on Diabetes Meds: April-December
  January 29, 2021

• Sumitomo Dainippon’s Half-Year Sales Up 13.4% on Latuda Growth
  October 29, 2020

• Sumitomo Dainippon’s Q1 Sales Up 13.9% on Equa/EquMet Contribution
  August 3, 2020